Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UTR-HER2-mBCa
- Development stage
- Preclinical
- Lead developer
- UTR Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
UTR-HER2-mBCa is an investigational RNA-based therapeutic developed by UTR Therapeutics for the treatment of metastatic HER2-positive (HER2+) trastuzumab-resistant breast cancer. The therapeutic utilizes a proprietary technology involving engineered destabilized 3' untranslated region (3'UTR) AU-rich elements (ARE) to selectively degrade HER2/ERBB2 mRNA transcripts. By replacing the naturally stable poly-U sequences in the 3'UTR of the ERBB2 gene with these destabilized sequences, the drug triggers the rapid degradation of the mRNA, leading to a significant reduction in HER2 protein expression. This mechanism is designed to overcome resistance mechanisms encountered with traditional HER2-targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors, and is currently in the IND-enabling stage of development.
- Other names
- UTR-HER2 RNA TherapeuticUTR-HER-2 RNA TherapeuticUTR-HER 2 RNA TherapeuticHER2/ERBB2-RNA Therapeutic
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on UTR-HER2-mBCa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTR-HER2-mBCa.